Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
Top Cited Papers
- 15 October 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (8) , 3002-3007
- https://doi.org/10.1182/blood-2002-04-1190
Abstract
Multiple myeloma (MM) is a hematologic malignancy characterized by accumulation of plasma cells in the bone marrow (BM). Bone destruction is a complication of the disease and is usually associated with severe morbidity. The balance between receptor activator of nuclear factor-κB (NF-κB) ligand and osteoprotegerin (OPG) is of major importance in bone homeostasis. We have recently shown that serum OPG levels are lower in patients with myeloma than in healthy individuals. Here we show that myeloma cells can bind, internalize, and degrade OPG, thereby providing a possible explanation for the lower levels of OPG in the BM of patients with MM. This process is dependent on interaction of OPG with heparan sulfates on the myeloma cells. The results suggest a novel biologic mechanism for the bone disease associated with MM and that treatment of the bone disease with OPG lacking the heparin-binding domain should be considered.Keywords
This publication has 40 references indexed in Scilit:
- Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progressionProceedings of the National Academy of Sciences, 2001
- Myeloma bone diseaseSeminars in Hematology, 2001
- RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolismProceedings of the National Academy of Sciences, 2000
- Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandProceedings of the National Academy of Sciences, 1999
- Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/OsteoprotegerinBiochemical and Biophysical Research Communications, 1998
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionNature, 1997
- TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T CellsJournal of Biological Chemistry, 1997
- Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits OsteoclastogenesisBiochemical and Biophysical Research Communications, 1997
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997